Recipharm, the Swedish contract development and manufacturing organisation (CDMO), has appointed Ann Flodin as General Manager of its wholly owned new subsidiary Recipharm Laboratories in Research Triangle Park, North Carolina, US, formerly Cirrus Pharmaceuticals.
Following the acquisition of Kemwell’s US development business in April, Flodin will be responsible for managing daily operations in Research Triangle Park and will focus on expanding and strengthening the development services that Recipharm offers to customers in the US.
With a background in chemical engineering, Flodin has more than 20 years’ experience in the pharmaceutical industry, with knowledge of both contract development and manufacturing services. She joined Recipharm in 1996 as a scientist within Process Engineering before moving on to manage the pharmaceutical development laboratory. She joins the Research Triangle Park business from a senior position in Group Operations Development and has previously been General Manager at Recipharm in Höganäs, Sweden.
Recipharm’s operations in Research Triangle Park will enable the firm to strengthen the support services it offers to pharmaceutical companies in the US. Recipharm will provide specialist pharmaceutical and analytical development services with a particular focus on inhalation, topical and transdermal products. In addition, the organisation will provide US customers with access to a broad range of capabilities and competencies from other parts of the Recipharm Group.
Flodin said: 'Having worked with Recipharm for 20 years and enjoyed the spirit and ambition of this fast-growing company, I am excited to now be part of our US endeavour. Our ultimate goal is to ensure Recipharm is the preferred partner for pharmaceutical development services worldwide.'
